| Autor: |
Ezzat, Tarek, Amr, Wesam, Mohamad, Hatem, Haggag, Rasha, Abd Allah, Mai Abd El Kader |
| Předmět: |
|
| Zdroj: |
Surgical Chronicles; 2019, Vol. 24 Issue 4, p185-190, 6p |
| Abstrakt: |
Background: preoperative chemotherapy can reduce the size of the tumor, thus allows some patients with advanced tumor the opportunity of conserving breast surgery. The aim of the study was to evaluate the efficacy of neoadjuvant chemotherapy (NC) on the possibility of breast-conserving surgery (BCS) in patients for whom mastectomy (MT) was the only accepted surgical option. Methods: between 2016 and 2019 thirty patients who had stage III breast cancer received neoadjuvant chemotherapy comprised of doxorubicin and cyclophosphamide, followed by surgery. Results: Among the 30 patients included, 27(90%) presented with an invasive ductal carcinoma. The mean tumor size before NCwas 37 mm (range, 20-75 mm) and 29 mm (range, 12.5-75 mm) after NC. Ten patients (33.3%) underwent BCS and 20 patients (66.7%) underwent MT. The mean follow-up survival time for all patients was 32±1.2 months range (29.8-34.8) months with (95% CI; 29.8-34.8). One case (3.3%) of BCS had locoregional recurrence and three cases (10%) had distant metastasis. Patients with IDC had significant higher DFS (33.5 ±1.04) months than patients with combined IDC+ILC (20±6) months and ILC (18) months. Patients with negative safety margin had significant higher DFS (33±1) months than patients with positive safety margin (19.5±6.7) months. Patients with MT had better numerical (not significant) DFS (32.25±1.5) months than patients with BCS (31.6±2.3) months. Conclusion: NC was effective in reducing the size of the tumor and should be applied in patients with advanced breast cancer. It improved local control and increased the chance of BCS without affecting overall survival. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
